The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Mustang Bio’s (NASDAQ:MBIO) lead drug MB-106 for the treatment of Waldenstrom macroglobulinemia (WM), a rare type of B-cell non-Hodgkin lymphoma (B-NHL).
MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center for patients suffering from relapsed or refractory B-NHLs and chronic lymphocytic leukemia (CLL).
The company is planning to begin patient enrolment in its multicenter Phase 1/2 clinical trial evaluating the safety and efficacy of MB-106 for relapsed or refractory B-NHL and CLL.
